View source for OSTEOPOROSIS-MANAGEMENT (DENOSUMAB)

===== [[Summary Article|'''SUMMARY''']] =====
1. Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody, RANK-ligand inhibitor which works by <i>preventing the development of osteoclasts</i> and reduces bone resorption.
<br/>
<br/>2. Used for the treatment of osteoporosis, drug-induced bone loss, bony metastases, and giant cell tumor of bone. 
<br/>2. Denosumab is contraindicated in people with low serum calcium levels. 
<br/>
<br/>3. The most common side effects are joint and muscle pain in the arms or legs.
<br/>
<br/>5. Given every 6 monthly.


==Reference(s)==
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. [https://amzn.to/3YHrI6K Get it on Amazon.]
<br/>Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. [https://amzn.to/3k7WSW0 Get it on Amazon.]
<br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
<br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].

[[Category:Osteoporosis]]
[[Category:Endocrinology]]
[[Category:Medicine]]